Oppenheimer Initiates Coverage On Fusion Pharmaceuticals with Outperform Rating, Announces Price Target of $13
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jeff Jones has initiated coverage on Fusion Pharmaceuticals (NASDAQ:FUSN) with an Outperform rating and a price target of $13.
September 29, 2023 | 9:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Fusion Pharmaceuticals has received an Outperform rating from Oppenheimer, with a price target set at $13.
The Outperform rating from Oppenheimer indicates a positive outlook for Fusion Pharmaceuticals. The price target of $13 suggests a potential upside from the current trading price. This could lead to increased investor interest and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100